Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion
Sponsors
GPOH gGmbH, Prinses Maxima Centrum voor Kinderoncologie B.V., Kite Pharma Inc., Centre Leon Berard, Charite Universitaetsmedizin Berlin KöR
Conditions
NeuroblastomaNewly diagnosed with an intracranial or spinal ependymoma (all WHO grades) including ependymoma variants: cellularRelapsed Acute Lymphoblastic Leukemia (ALL)Relapsed/Refractory Follicular LymphomaStage IV childhood renal tumour with pulmonary +/- non-pulmonary
metastasisclear-cell and tanycytic or anaplastic ependymoma.myxopapillarypapillary
Phase 1
Phase 2
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease Committee of the International BFM Study Group – IntReALL HR 2010
Active, not recruitingCTIS2024-513070-21-00
Start: 2018-02-15Target: 222Updated: 2025-09-17
SIOP Ependymoma Program II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma
RecruitingCTIS2024-512222-28-00
Start: 2015-06-02Target: 876Updated: 2024-12-09
Phase 3
Randomized multi-centre open-label non-inferiority phase 3 clinical trial for patients with a stage IV childhood renal tumour comparing upfront Vincristine, Actinomycin-D and Doxorubicin (VAD, standard arm) with upfront Vincristine, Carboplatin and Etoposide (VCE, experimental arm)
RecruitingCTIS2023-508926-91-00
Start: 2019-12-05Target: 309Updated: 2026-01-14
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
Active, not recruitingCTIS2024-511594-30-00
Start: 2023-02-23Target: 142Updated: 2026-01-14